about
Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.Evolution of the incidence of inflammatory bowel disease in Southern Spain.Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.Ileocecal endometriosis as an infrequent cause of intussusception.Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel diseaseLong-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 MonthsSingle colonic polyp as a presentation of mantle cell lymphoma
P50
Q33843746-ED7184D7-0233-4CF4-8E95-6DC29566BF6DQ38641635-A97769D4-350B-4636-96AE-D93F7112EF16Q42701889-A0BDA333-88B2-4C9D-B24A-AD583AA29CD6Q49576602-8E7A1C70-35F2-4693-A7BF-E09660B37C4CQ60302346-EF58DFCD-A8F7-48B7-9EA3-C442B96C6EF6Q64983137-16CD069F-F593-494B-A8C8-A7A8E4E49C79Q88412754-6D1EAE85-334B-4082-9E72-274E27D7E27AQ88943590-0AC67E57-CC3A-4C54-A8CA-25181C6D324A
P50
description
researcher
@en
wetenschapper
@nl
name
M F Guerra Veloz
@en
M F Guerra Veloz
@nl
type
label
M F Guerra Veloz
@en
M F Guerra Veloz
@nl
prefLabel
M F Guerra Veloz
@en
M F Guerra Veloz
@nl
P31
P496
0000-0001-9708-8245